ArticleBioMed research international2022
Investigating the Lung Adenocarcinoma Stem Cell Biomarker Expressions Using Machine Learning Approaches.
Article in BioMed research international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Analysis and identification of mRNAsi‑related expression signatures via RNA sequencing in lung cancer.Oncology letters · 2024Article
- Retracted: Investigating the Lung Adenocarcinoma Stem Cell Biomarker Expressions Using Machine Learning Approaches.BioMed research international · 2024Article
Corrections and comments
- Retraction · 2024-01-09Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Paper Mill · Computer-Aided Content or Computer-Generated Content · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of the study is to look at the activation of stem cell-related markers in lung adenocarcinoma. Utilizing an unsupervised machine learning approach centered on the mRNA expression of pluripotent stem cells as well as its subsequent developed progeny, the mRNA stemness index of further around 500 LUAD patients from The Cancer Genome Atlas dataset was generated. In LUADs, mRNAsi had first been investigated using differential variations, survivability analyses, medical phases, and sexuality. A computational approach is used for identifying cell clusters utilizing fuzzy clustering. There at transcriptional as well as protein stages, the interactions between the genetic markers were investigated. The functionality and processes of the important genes were annotated using expression values. The degree of gene expression related to the clinical symptoms and the likelihood of surviving have also been confirmed. In cancer patients, the mRNAsi genes were highly elevated. In particular, the mRNAsi score rises with advanced trials and varies markedly by sexuality. Within several years, reduced mRNAsi categories will have superior overall survivability in large LUADs. Individuals with chronic LUAD had greater mRNAsi and had reduced average survivability. The important genes and the distinguished categories have been chosen based on their mRNAsi connections. Some of the major genes related to cell proliferating Gene Ontology concepts were found enriched out from the cell cycle Kyoto Encyclopedia of Genes and Genomes (KEGG) process. Specific genes were found to be linked to CSC features. Their activation grew in lockstep with the progression of LUAD's pathology, so these markers appeared amplified in pan-cancers. These important markers were discovered to have substantial connections as a group, suggesting that they could be exploited as drug applications in the therapy of LUAD by suppressing stemness traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.